FDA Sarclisa Approval Marks Sanofi's Reentry Into Oncology
Executive Summary
The anti-CD38 antibody will face an entrenched rival, J&J's Darzalex, for multiple myeloma.
You may also be interested in...
What Sanofi Early Research Chief Scientist Frank Nestle Is Most Excited About
Sanofi's Nestle talked to Scrip about the company's early pipeline, the emerging technologies he thinks are most promising and tapping external innovation.
What Sanofi Early Research Chief Scientist Frank Nestle Is Most Excited About
Sanofi's Nestle talked to In Vivo about the company's early pipeline, the emerging technologies he thinks are most promising, and tapping external innovation.
J.P. Morgan Day 2: Pharma Offers (Some) Views On Drug Pricing Reform
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Novartis explains its PD-1 deal; Biogen partners with Apple; Sanofi and Merck discuss business development priorities; and why AbbVie is confident it can grow without relying on deals.